We are excited to introduce this new premium line of microdose and apaptogens from a Canadian company: Be Yourself (Core) Microdose Psilocybin Capsules
Be Mushrooms comes in “Core” and 4 different “Boosters”. The Core product “Be Yourself” contains psilocybin that we’ve all come to love. Although psilocybin has large profound effects, Be Mushrooms developed “Boosters” to take advantage of Earth’s most beneficial nootropics. Each booster contains various adaptogens that have their own unique properties that synergize well with one another. Be Yourself and Be Boosters can be taken individually or stacked together depending on your goals.
Designed to be the perfect microdose of Psilocybin, Be Yourself is proven to promote optimum mental health. Sourced from 100% organic psilocybe cubensis, it is known to regulate one’s mood by reducing the effects of stress, anxiety, and depression. With continued use, studies show an increase in one’s overall sense of well-being to truly be the best version of yourself.
Be Yourself (Core) Microdose Psilocybin Capsules
Recommended Use: Promotes optimum mental health and regulates mood by reducing stress, anxiety, and depression. Increases overall sense of well-being so you can feel like the best version of yourself.
Each glass bottle contains: 50 capsules x 100mg Psilocybe Cubensis
Be mushrooms is made in Canada, Organic, Vegan and Non GMO
Although Psilocybin (the active ingredient in magic mushrooms) has large profound effects, Be formulated “Boosters” to supercharge your wellness even further and introduce some of the earth’s most beneficial nootropics. These mushrooms have been used for centuries in different parts of the world and have been scientifically proven to offer a wide host of benefits. Each of the various adaptogens has its own unique properties that synergize well with one another. Be Yourself and Be Boosters are formulated so they can be taken individually or stacked together depending on your goals.
Recommended Dose: Dosing schedules can vary based on individual preference. Please refer to our FAQ to find a schedule that best suits your needs.
The benefits of full-dose psychedelics
While more than a thousand early studies linked psychedelic use with beneficial effects , there was a 40-year pause on psychedelic research following the prohibition of these substances . Despite continued prohibition, modern research has revealed the promising potential of LSD and psilocybin for treating alcohol and tobacco dependence [14,15,16,17], depression [18, 19], and end-of-life anxiety [20,21,22], while related research on 3,4-methylenedioxymethamphetamine (MDMA) has shown great promise for treating post-traumatic stress disorder . Psychedelics can also increase openness and occasion mystical-type experiences in healthy controls [24,25,26]. As full-dose psychedelics appear to aide in the relief of severe, chronic psychiatric conditions (e.g. depression, anxiety, PTSD), milder mental health concerns may plausibly be treated by lower, recurring doses. This is especially worth considering if certain full-dose outcomes are found to rely on purely pharmacologic mechanisms rather than primarily on phenomenological experiences .
Limiting microdosing research to topics that have been investigated in full-dose research could prematurely overlook unpredicted and potentially distinct microdosing outcomes. Full-dose research has employed various focal assessments of symptomatology, mood, and personality that are likely applicable to microdosing research, but due to the low doses and lack of perceptual alteration intended in microdosing, other full-dose phenomena, such as ego dissolution and mystical-type experiences, are less relevant to microdosing research. Instead, as a means of preparing for a broad range of outcomes, the present work solicited open-ended reports of benefits and challenges. Additionally, as psychedelic substances act on distinct yet overlapping neural receptor sites, it seems plausible that distinct patterns could emerge for different substances. The present study thus included microdosers who used LSD, psilocybin, or both.